NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs

1. State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?

Publication:
[Washington, D.C.] : AcademyHealth, [2005]
Subject(s):
Cost Control
Medicare -- economics
State Health Plans -- economics
Cost Sharing
Drug Costs
Drug Utilization Review
Drugs, Generic
Fees, Pharmaceutical
Formularies as Topic
Insurance Coverage -- legislation & jurisprudence
Insurance, Pharmaceutical Services -- economics
Insurance, Pharmaceutical Services -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Humans
United States

3. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

4. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Medicare -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

5. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2017
Subject(s):
Drug Costs
Insurance, Pharmaceutical Services -- economics
Medicare Part B -- economics
Prospective Payment System
Abatacept -- economics
Certolizumab Pegol -- economics
Cost Savings
Injections -- economics
Self Care -- economics
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)
Healthcare common procedure coding system

6. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

7. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2018
Subject(s):
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Cost Savings
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

10. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
Financing, Personal
Health Services Accessibility
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Protein Kinase Inhibitors -- economics
Protein Kinase Inhibitors -- therapeutic use
Protein-Tyrosine Kinases -- antagonists & inhibitors
Humans
United States

13. Trends in P2Y12 receptor inhibitor use and adherence after percutaneous coronary intervention, 2008-2016

Author(s):
Dayoub, Elias J., author
Seigerman, Matthew, author
Tuteja, Sony, author
Kobayashi, Taisei, author
Kolansky, Daniel, author
Giri, Jay, author
Groeneveld, Peter, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Medication Adherence -- statistics & numerical data
Percutaneous Coronary Intervention
Purinergic P2Y Receptor Antagonists -- therapeutic use
Socioeconomic Factors
Drug Costs
Drugs, Generic -- economics
Drugs, Generic -- therapeutic use
Platelet Aggregation Inhibitors -- economics
Platelet Aggregation Inhibitors -- therapeutic use
Purinergic P2Y Receptor Antagonists -- economics
Social Determinants of Health
Humans
United States

15. The Medi-Cal prescription drug benefit: an overview

Publication:
Oakland, Calif. : California HealthCare Foundation, [2009]
Subject(s):
Health Expenditures -- trends
Insurance Benefits
Insurance, Pharmaceutical Services
Medicaid
Prescription Drugs -- economics
Adult
Aged
Child
Cost Control
Cost Sharing
Disabled Persons
Drug Costs
Drug Utilization Review
Drugs, Generic
Fee-for-Service Plans
Forecasting
Managed Care Programs
Medicare Part D
Middle Aged
Humans
California

16. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

17. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

18. Bending the curve: options for achieving savings and improving value in U.S. health spending

Publication:
[New York, N.Y.] : Commonwealth Fund Commission on a High Performance Health System, [2007]
Subject(s):
Cost Savings
Health Expenditures -- trends
Quality Assurance, Health Care
Decision Making
Drug Costs
Forecasting
Federal Government
Health Policy
Health Promotion
Insurance Coverage
Insurance, Health
Medical Informatics
Obesity -- prevention & control
Smoking Cessation -- economics
State Government
Humans
United States

19. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

20. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, July 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Delivery of Health Care
Health Policy
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment -- economics
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- rehabilitation
Analgesics, Opioid -- administration & dosage
Analgesics, Opioid -- adverse effects
Budgets
Cohort Studies
Cost-Benefit Analysis
Counseling
Criminal Law
Drug Combinations
Drug Costs
Health Services Accessibility
Insurance Coverage
Medicaid
Medicare
Patient Care Team
Patient-Centered Care
Practice Guidelines as Topic
Treatment Outcome
Humans
New England
United States

21. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins-Domingo, Kirsten, author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
Cholesterol, LDL
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Resistance
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Value-Based Purchasing
Humans
New England
United States

22. CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Ollendorf, Daniel A., author
Ollendorf, Daniel A., author
Tarlochan Sandhu, Alexander, author
Chapman, Rick, author
Heidenreich, Paul A., author
Russo, Elizabeth, author
Shore, Karen K., author
Synnott, Patricia, author
Travers, Karin, author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 1, 2015
Subject(s):
Angiotensin II Type 1 Receptor Blockers -- administration & dosage
Antihypertensive Agents -- administration & dosage
Blood Pressure Monitoring, Ambulatory -- instrumentation
Blood Pressure Monitoring, Ambulatory -- methods
Heart Failure -- diagnosis
Heart Failure -- drug therapy
Neprilysin -- administration & dosage
Tetrazoles -- administration & dosage
Valsartan -- administration & dosage
Angiotensin II Type 1 Receptor Blockers -- economics
Antihypertensive Agents -- economics
Cost-Benefit Analysis
Drug Combinations
Drug Costs
Neprilysin -- antagonists & inhibitors
Neprilysin -- economics
Outcome and Process Assessment (Health Care)
Tetrazoles -- economics
Valsartan -- economics
Humans
United States

23. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

24. Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit

Author(s):
Pearson, Steven D., author
Dreitlein, Bill, author
Henshall, Chris, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Drug Costs
Economics, Pharmaceutical
Insurance, Pharmaceutical Services -- economics
Prospective Payment System
Reimbursement Mechanisms -- economics
Cost Savings
Cost Sharing
Formularies
Medicaid -- economics
Medicare -- economics
Off-Label Use -- economics
Pilot Projects
Value-Based Purchasing
Humans
United States

25. Does Medicare Part D protect the elderly from financial risk?

Author(s):
Englehardt, Gary V., author
Gruber, Jonathan, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, June 2011
Subject(s):
Financing, Personal
Health Services for the Aged -- economics
Insurance Coverage -- economics
Medicare Part D -- economics
Risk Sharing, Financial
Aged
Drug Costs
Forecasting
Health Care Surveys
Health Expenditures -- statistics & numerical data
Insurance Coverage -- statistics & numerical data
Medicare Part D -- statistics & numerical data
Medicare Part D -- trends
Prescription Drugs -- economics
Socioeconomic Factors
Humans
United States

27. No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending

Author(s):
Cubanski, Juliette, author
Neuman, Tricia, author
Orgera, Kendal, author
Damico, Anthony, author
Publication:
Menlo Park, CA : Henry J. Kaiser Family Foundation, November 2017
Subject(s):
Drug Costs
Financing, Personal
Health Expenditures
Medicare Part D -- economics
Medicare Part D -- trends
Chronic Disease -- drug therapy
Chronic Disease -- economics
Demography
Hepatitis C -- drug therapy
Leukemia -- drug therapy
Lymphoma -- drug therapy
Poverty
Humans
United States

28. Medicare and mental health: the fundamentals

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Insurance Coverage
Medicare -- economics
Mental Disorders -- economics
Mental Health -- statistics & numerical data
Community Mental Health Services -- economics
Disabled Persons
Disease Management
Drug Costs
Health Expenditures
Hospitalization -- economics
Insurance, Pharmaceutical Services
Medicaid -- economics
Medicare -- statistics & numerical data
Mental Disorders -- epidemiology
Mental Disorders -- therapy
Mental Health Services -- economics
Prevalence
Psychotropic Drugs -- economics
Humans
United States
Medicare Payment Advisory Commission (U.S.)

29. Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Armstrong, Katrina A., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2018
Subject(s):
Antineoplastic Agents -- economics
Antineoplastic Agents -- therapeutic use
Drug Costs
Financing, Personal -- statistics & numerical data
Medication Adherence -- statistics & numerical data
Administration, Oral
Antineoplastic Agents -- administration & dosage
Health Services Accessibility
Prescription Drugs -- economics
Socioeconomic Factors
Time Factors
Humans
United States

33. Reducing potential overuse of dementia drugs could lead to considerable savings

Author(s):
Carter, Elizabeth A., author
Purvis, Leigh, author
Publication:
Washington, DC : AARP Public Policy Institute, August 2018
Subject(s):
Dementia -- drug therapy
Dementia -- economics
Drug Costs
Inappropriate Prescribing -- economics
Aged
Cholinesterase Inhibitors -- economics
Cholinesterase Inhibitors -- therapeutic use
Cost Savings
Drug Therapy, Combination
Memantine -- economics
Memantine -- therapeutic use
Humans
United States

34. Top spenders among commercially-insured: increased spending concentration and consistent turnover from 2013 to 2015

Author(s):
Johnson, Bill, author
Rodriguez, Sally, author
Publication:
Washington, DC : Health Care Cost Institute, February 2018
Subject(s):
Financing, Personal
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Drug Costs
Forecasting
Insurance, Health -- economics
Insurance, Pharmaceutical Services -- economics
Private Sector
Humans
United States

35. The rising cost of specialty drugs drove spending increases for people with multiple sclerosis

Author(s):
Johnson, Bill, author
Publication:
Washington, DC : Health Care Cost Institute, April 2018
Subject(s):
Drug Costs
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Multiple Sclerosis -- economics
Multiple Sclerosis -- drug therapy
Dihydroorotate Oxidase -- antagonists & inhibitors
Dimethyl Fumarate -- economics
Fingolimod Hydrochloride -- economics
Forecasting
Glatiramer Acetate -- economics
Interferon beta-1a -- economics
Interferon beta-1b -- economics
Humans
United States

36. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, November 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)

37. Medicare Part B: Medicare represented at least half of the market for 22 of the 84 most expensive drugs in 2015 : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, December 2017
Subject(s):
Drug Costs
Health Care Sector
Health Expenditures
Medicare Part B -- economics
Insurance, Health, Reimbursement
Medicare Part B -- statistics & numerical data
Humans
United States

42. The ABCs of APCDs: how states are using claims data to understand and improve care

Author(s):
Porter, Josephine, author
Love, Denise, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, November 2018
Subject(s):
Databases as Topic
Health Expenditures -- statistics & numerical data
Insurance Claim Review
Chronic Disease -- economics
Cost of Illness
Drug Costs
Health Care Costs
Inappropriate Prescribing -- prevention & control
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- epidemiology
State Government
Humans
California
United States

43. Report on the affordability of insulin

Author(s):
Finegold, Kenneth, 1957- author
Sayed, Bisma A., author
Publication:
Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 16, 2022
Subject(s):
Costs and Cost Analysis
Drug Costs
Health Expenditures
Insulin -- economics
Diabetes Mellitus -- drug therapy
Diabetes Mellitus -- economics
Medication Adherence
United States

45. A sense of déjà vu: the debate surrounding state biosimilar substitution laws

Author(s):
Purvis, Leigh, author
Publication:
Washington, D.C. : AARP Public Policy Institute, September 2014
Subject(s):
Biological Products -- economics
Biological Products -- therapeutic use
Biosimilar Pharmaceuticals -- economics
Biosimilar Pharmaceuticals -- therapeutic use
Drug Costs
Drug Substitution
Legislation, Drug
Drugs, Generic -- economics
Federal Government
State Government
Humans
United States
United States. Food and Drug Administration.
United States.

46. How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 2020

Author(s):
Gifford, Kathleen, author
Winter, Anne, author
Wiant, Linda, author
Dolan, Rachel, author
Tian, Marina, author
Garfield, Rachel, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, April 2020
Subject(s):
Cost Control
Drug Costs
Medicaid
State Government
United States

61. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

64. Quality of healthcare

Author(s):
Brude, Sydney, author
White, Robert S., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Legislation, Medical
Patient Safety -- legislation & jurisprudence
Quality of Health Care -- legislation & jurisprudence
Ambulatory Care Facilities -- legislation & jurisprudence
Drug Costs
Elder Abuse
Equipment Failure
Equipment Safety
Health Facilities -- legislation & jurisprudence
Legislation, Hospital
Medicare
Nursing Homes -- legislation & jurisprudence
Quality Indicators, Health Care -- legislation & jurisprudence
State Government
Surgicenters
Veterans Health
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

65. Administrative rulemaking

Author(s):
Berry, Melissa D., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Health Care Reform -- legislation & jurisprudence
Advertising -- legislation & jurisprudence
Conscientious Refusal to Treat -- legislation & jurisprudence
Contraception
Drug Costs
Emergency Medical Services -- legislation & jurisprudence
Emigrants and Immigrants -- legislation & jurisprudence
Hospital Costs
Insurance, Health, Reimbursement
Long-Term Care
Medicaid -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Politics
Taxes
Transportation of Patients -- legislation & jurisprudence
Humans
United States
United States. Department of Health and Human Services.
United States.
Centers for Medicare & Medicaid Services (U.S.)

66. Insurance market reform:

Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Health Care Reform -- economics
Health Care Reform -- legislation & jurisprudence
Health Care Reform -- trends
Health Insurance Exchanges -- economics
Health Insurance Exchanges -- legislation & jurisprudence
Health Insurance Exchanges -- trends
Insurance, Health -- economics
Insurance, Health -- legislation & jurisprudence
Insurance, Health -- trends
Drug Costs
Forecasting
Federal Government
Medicaid
State Government
Humans
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)

67. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

68. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, May 15, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration.

70. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, July 11, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration.

71. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):
Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

72. MAT for hospitalized patients

Author(s):
Newman, Sandra, author
Publication:
[Oakland, California] : California Health Care Foundation, June 2019
Subject(s):
Hospitalization
Inpatients
Insurance, Health, Reimbursement
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Drug Costs
Hospital Costs
Methadone -- therapeutic use
Reimbursement Mechanisms
State Government
Humans
California
United States

74. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Author(s):
Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022
Subject(s):
Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States

81. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, September 2023
Subject(s):
Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)